A study led by scientists at Osaka University Graduate School of Medicine has identified the previously unknown molecular mechanism underlying bone marrow regeneration after chemotherapy, which damages hematopoietic stem and progenitor cells.
Keeping you up to date on recent developments in neurology, including: AI reveals drugs that may be repurposed for Alzheimer’s disease; Treating Parkinson’s disease symptoms with brain cell grafts; Astrocytes are more inflammatory in bipolar disease; Pain on the brain.
DUBLIN – A novel real-world study methodology that marries digital technology with a citizen science or do-it-yourself approach to “drug” procurement, formulation and administration has found – yet again – that the placebo remains one of the great wonders of the medical world.
Keeping you up to date on recent developments in diagnostics, including: Rapid POC test for respiratory infections may reduce antibiotic use; Risk-stratification tools help conserve ventilator, ICU bed use; Diverse populations, long reads give genome insights; Neurons contribute to their own lack of regeneration.
At the 2021 Advances in Genome Biology and Technology meeting, John Greally had some unusual advice with respect to confounders in epigenomic studies. Epigenomics, he told the audience in his talk on "Thinking beyond the creode: epigenomics and human disease," has real promise for understanding genomic mechanisms of disease. "But possibly not in the way we think."
Keeping you up to date on recent developments in orthopedics, including: Treating rheumatoid arthritis with micromotors; Bioengineered hybrid muscle fiber for regenerative medicine; Immunosuppressive cell and cytokine response linked to bone nonunion.
"Nothing is undruggable!" was the bold claim at the European Society of Medical Oncology Targeted Anticancer Therapies Virtual Congress 2021 the (ESMO-TAT).
In the public mind, fat and unhealthy are more or less synonymous. But reality is more complicated, as reality often is. Even among individuals with a BMI of 30 or higher, somewhere between 15% and 45% have metabolism typical of much lower-weight individuals.
Scientists, despite their best efforts, have not been able to identify a way to inhibit the oncoprotein Myc. Uropathogenic Escherichia coli, though, has apparently figured it out. In the Feb. 11, 2021, online issue of Nature Biotechnology, researchers reported that an UPEC-produced protease depleted cellular Myc and improved survival in mouse models of bladder and colon cancer.